Relationships of platelet glycoprotein specific antibody with therapeutic efficacy of short-term high-dose dexamethasone and bleeding score in the newly diagnosed adult patients with primary immune thrombocytopenia

References

• Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107:615–623. doi:10.1007/s12185-018-2445-z
   PubMed Web of Science ®Google Scholar
• Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945–955. doi:10.1056/NEJMcp1810479
   PubMed Web of Science ®Google Scholar
• Chen JF, Yang LH, Chang LX, et al. The clinical significance of circulating B cells secreting anti-glycoproteinIIb/IIIa antibody and platelet glycoprotein IIb/IIIa inpatients with primary immune thrombocytopenia. Hematology. 2012;17(5):283–290. doi:10.1179/1607845412Y.0000000014
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260–267. doi:10.1111/bjh.12869
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302. quiz 370, doi:10.1182/blood-2015-07-659656
   PubMed Web of Science ®Google Scholar
• Thrombosis and Hemostasis Group. Chinese Society of Hematology, Chinese Medical Association. [Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(8):617–623. Chinese, doi:10.3760/cma.j.issn.0253-2727
   PubMedGoogle Scholar
• Frederiksen H, Ghanima W. Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. Eur J Intern Med. 2017;37:e23–e25. doi:10.1016/j.ejim.2016.09.001
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang X, Feng S, et al. Clinical efficacy of high-dose dexamethasone with sequential prednisone maintenance therapy for newly diagnosed adult immune thrombocytopenia in a real-world setting. J Int Med Res. 2021;49(4):3000605211007322, doi:10.1177/03000605211007322
   Web of Science ®Google Scholar
• Khan AM, Mydra H, Nevarez A. Clinical practice updates in the management of immune thrombocytopenia. P T. 2017;42(12):756–763. PMID: 29234214.
   PubMedGoogle Scholar
• Song F, Al-Samkari H. Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice. J Blood Med. 2021;12:653–664. doi:10.2147/JBM.S259101
   PubMed Web of Science ®Google Scholar
• Mishra K, Kumar S, Singh K, et al. Real-world experience of anti-D immunoglobulin in immune thrombocytopenia. Ann Hematol. 2022;101(6):1173–1179. doi:10.1007/s00277-022-04829-4
   PubMed Web of Science ®Google Scholar
• Mishra K, Kumar S, Jandial A, et al. Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 2020;10(5):240–251. PMID: 3322456.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020;4(1):9–18. doi:10.1182/bloodadvances.2019000868
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Li Y, et al. Immune dysregulation in primary immune thrombocytopenia patients. Hematology. 2018;23(8):510–516. doi:10.1080/10245332.2018.1435021
   PubMed Web of Science ®Google Scholar
• Caserta S, Zaccuri AM, Innao V, et al. Immune thrombocytopenia: options and new perspectives. Blood Coagul Fibrinolysis. 2021;32(7):427–433. doi:10.1097/MBC.0000000000001058
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521. doi:10.1182/blood-2009-01-129155
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu J, Chen Y. Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia. Exp Hematol Oncol. 2021;10(1):21, doi:10.1186/s40164-021-00214-5
   PubMed Web of Science ®Google Scholar
• Zheng SS, Ahmadi Z, Leung HHL, et al. Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia. Haematologica. 2022;107(9):2195–2205. doi:10.3324/haematol.2021.279751
   PubMed Web of Science ®Google Scholar
• Sirotich E, Guyatt G, Gabe C, et al. Definition of a critical bleed in patients with immune thrombocytopenia: communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021;19(8):2082–2088. doi:10.1111/jth.15368
   PubMed Web of Science ®Google Scholar
• Hirokawa M, Fujishima N, Togashi M, et al. High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/IGHJ4 gene in primary immune thrombocytopenia. Sci Rep. 2019;9(1):8645, doi:10.1038/s41598-019-45264-2
   PubMedGoogle Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129:2829–2835. doi:10.1182/blood-2017-03-754119
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbα antibodies. Am J Hematol. 2012;87(2):206–208. doi:10.1002/ajh.22211
   PubMed Web of Science ®Google Scholar
• Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497–504. doi:10.1111/jth.12524
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi:10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24:3669–3676. doi:10.1007/s00520-016-3297-9
   PubMed Web of Science ®Google Scholar
• Mishra K, Kumar S, Sandal R, et al. Safety and efficacy of splenectomy in immune thrombocytopenia. Am J Blood Res. 2021;11(4):361–372. PMID: 34540344.
   PubMedGoogle Scholar
• Vianelli N, Auteri G, Buccisano F, et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. 2022;101(5):963–978. doi:10.1007/s00277-022-04786-y
   PubMed Web of Science ®Google Scholar
• Terrell DR, Neunert CE, Cooper N, et al. Immune thrombocytopenia (ITP): current limitations in patient management. Medicina (Kaunas. 2020;56(12):667, doi:10.3390/medicina56120667
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Du Y, Yang C, Chen M, et al. Tacrolimus is effective in relapsed/refractory autoimmune cytopenias: results of a single-center retrospective study. Hematology. 2020;25(1):478–483. doi:10.1080/16078454.2020.1852763
   PubMed Web of Science ®Google Scholar
• Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353–357. doi:10.1034/j.1600-0609.2003.00076.x
   PubMed Web of Science ®Google Scholar
• George NP, Wei Q, Shin PK, et al. Staphylococcus aureus adhesion via Spa, ClfA, and SdrCDE to immobilized platelets demonstrates shear-dependent behavior. Arterioscler Thromb Vasc Biol. 2006;26(10):2394–2400. doi:10.1161/01.ATV.0000237606.90253.94
   PubMed Web of Science ®Google Scholar
• Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):515–519. doi:10.1097/MOH.0b013e3282ab98c7
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(23):831–836. doi:10.1056/NEJMoa.030254
   PubMed Web of Science ®Google Scholar
• Matschke J, Müller-Beissenhirtz H, Novotny J, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naïve adult patients with immune thrombocytopenia: EIS 2002 study. Acta Haematol. 2016;136(2):101–107. doi:10.1159/000445420
   PubMed Web of Science ®Google Scholar
• Liu X, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol. 2023;16(4), doi:10.1186/s13045-023-01401-z
   Google Scholar
• Kuwana M, Okazaki Y, Kaburaki J, et al. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 2003;114(4):322–325. doi:10.1016/s0002-9343(02)01522-x
   PubMed Web of Science ®Google Scholar
• Nomura S, Yanabu M, Soga T, et al. Analysis of idiopathic thrombocytopenic purpura patients with antiglycoprotein IIb/IIIa or Ib autoantibodies. Acta Haematol. 1991;86(1):25–30. doi:10.1159/000204794
   PubMed Web of Science ®Google Scholar
• Scull CM, Hays WD, Fischer TH. Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm (Lond). 2010;7:53, doi:10.1186/1476-9255-7-53
   PubMed Web of Science ®Google Scholar
• Vollenberg R, Jouni R, Norris PAA, et al. Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. Haematologica. 2019;104(6):1237–1243. doi:10.3324/haematol.2018.211086
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Bergmeier W, Rackebrandt K, et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520–2527. PMID: 11001906. doi:10.1182/blood.V96.7.2520
   PubMed Web of Science ®Google Scholar
• Campbell K, Rishi K, Howkins G, et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicenter evaluation. Vox Sang. 2007;93(4):289–297. doi:10.1111/j.1423-0410.2007.00989.x.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Canouï-Poitrine F, Croisille L, et al. Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding. Ann Hematol. 2014;93(2):309–315. doi:10.1007/s00277-013-1855-5
   PubMed Web of Science ®Google Scholar
• Arnold DM, Santoso S, Greinacher A, et al. Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. J Thromb Haemost. 2012;10(4):695–697. doi:10.1111/j.1538-7836.2012.04664.x
   PubMedGoogle Scholar
• Rodeghiero F, Marranconi E. Management of immune thrombocytopenia in women: current standards and special considerations. Expert Rev Hematol. 2020;13(2):175–185. doi:10.1080/17474086.2020.1711729
   PubMed Web of Science ®Google Scholar